Effect of zinc and omega-3 supplements as adjuvant therapy in children with attention-deficit hyperactivity disorder

Effect of zinc and omega-3 supplements in children with attention-deficit hyperactivity disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104166201N1

Enrollment

150

Registered

2011-05-13

Start date

2011-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder. Hyperkinetic disorders

Interventions

Intervention 1: Children will receive omega-3 supplement and Ritalin in the third group. Dose of omega-3 supplement is based on the weight of the child as follows: children less than 25 kg ,100 mg o

Treatment - Drugs

Placebo

Children will receive omega-3 supplement and Ritalin in the third group. Dose of omega-3 supplement is based on the weight of the child as follows: children less than 25 kg ,100 mg of EPA children b

Children will receive placebo with Ritalin in the first group.

Children will receive Zinc supplement 15mg daily and placebo in the second group.

Eligibility

Sex/Gender

All

Age

6 Years to 15 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Age: 6-15 years, 2. Newly diagnosed patient, 3. No history of taking any psychiatric drug, 4. No other psychiatric disorders, 5. There is no contraindication for the use of zinc and omega 3, 6. Diagnosis of ADHD is based on diagnostic criteria in DSM IV and diagnostic interview of psychiatrist. Exclusion criteria: 1. Parents or children withdrew the study because of any reason, 2. Child is suffering from acute physical illness, 3. Children can’t use oral drugs, 4. Complications of drugs is so high that we have to stop them, 5. Alter treatment, 6. The drug is not used, 7. Any previous psychiatric disorders, 8. Mental retardation, 9. The patient can’t use drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Scores in questionnaire. Timepoint: before treatment and then 2 weeks, 4 and 8 weeks after treatment. Method of measurement: 48 questions Conner's Rating Scals questionnaire.	—

Secondary

Measure	Time frame
Adverse reactions. Timepoint: 2 weeks, 4 weeks and 8 weeks after treatment. Method of measurement: drug adverse reactions questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Dorreh

Arak University of Medical Sciences

fatemeh_dorre@yahoo.com+98 86 1313 4715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026